Abstract
Thrombolytic treatment of patients with acute myocardial infarction is now well accepted as the treatment of choice in most settings (24). At this time most data has been accumulated with the use of streptokinase, and this drug has been convincingly demonstrated to reduce mortality (5). Reperfusion is achieved in 45–75% of patients, with direct intracoronary administration being slightly more effective than administration by the intravenous route (25). Some problems remain, bleeding is significant and rethrombosis continues to be an obstacle (7).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S. R. Bergmann, K. A. Fox, M. M. Ter Pogossian, B. E. Sobel, and D. Collen, Clot-selective coronary thrombolysis with tissue-type plasminogen activator, Science, 220:1181–1183 (1983).
D. Collen, E. J. Topol, A. J. Tiefenbrunn, H. K. Gold, M. L. Weisfeldt, B. E. Sobel, R. C. Leinbach, J. A. Brinker, P. A. Ludbrook, I. Yasuda, N. H. Bulkley, A. K. Robison, A. M. Jr. Hutter, W. R. Bell, J. J. Jr. Spadaro, B. A. Khaw, and E. B. Grossbard, Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial, Circulation, 70:1012–1017 (1984).
T. Eckhardt, H. L. Nossel, A. Hurlet Jensen, K. S. LaGamma, J. Owen, and M. Auerbach, Measurement of desarginine fibrinopeptide B in human blood, J. Clin. Invest., 67:809–816 (1981).
W. Flameng, F. Van de Werf, J. Vanhaecke, M. Verstraete, and D. Collen, Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates, J. Clin. Invest., 75:84–90 (1985).
GISSI. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction, Lancet,397–401 (1986).
H. K. Gold, R. C. Leinbach, H. D. Garabedian, T. Yasuda, J. A. Johns, E. B. Grossbard, I. Palacios, and D. Collen, Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion, Circulation,73:347–352 (1986).
H. K. Gold, R. C. Leinbach, I. F. Palacios, T. Yasuda, P. C. Block, M. J. Buckley, C. W. Akins, and W. M. Daggett, Coronary reocclusion after selective administration of streptokinase, Circulation, 68:150–154 (1983).
B. Kudryk, A. Rohoza, M. Ahadi, J. Chin, and M. E. Wiebe, Specificity of a monoclonal antibody for the NH2-terminal region of fibrin, Mol. Immunol., 21:89–94 (1984).
C. Y. Liu, J. H. Sobel, J. I. Weitz, K. L. Kaplan, and H. L. Nossel, Immunologic identification of the cleavage products from the A-alpha and B-beta chains in the early stages of plasmin digestion of fibrinogen. Thrombos Haemostas, 56:100–106 (1986).
V. J. Marder, N. R. Shulman, and W. R. Carroll, The importance of intermediate degradation products of fibrinogen in fibrinolytic hemorrhage, Trans. Assoc. Am. Physicians, 80:156–167 (1967).
R. P. McDonagh, J. McDonagh, and F. Duckert, The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Brit. J. Haematol., 21:232–332 (1971).
H. L. Nossel, J. Wasser, K. L. Kaplan, K. S. LaGamma, I. Yudelman, and R. E. Canfield, Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline, J. Clin. Invest., 64:1371–1378 (1979).
J. Owen, K. D. Friedman, B. Grossman, C. Wilkins, A. D. Berke, and E. R. Powers, Quantitation of fragment X formation during thrombolytic therapy with streptokinase and with tissue plasminogen activator, J. Clin. Invest., 79:1642–1649 (1987).
J. Owen, K. D. Friedman, B. A. Grossman, C. Wilkins, A. D. Berke, and E. R. Powers, Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin action. Blood, 72:616–620 (1988).
D. Pennica, W. E. Holmes, W. J. Kohr, R. N. Harkins, G. A. Vehar, C. A. Ward, W. F. Bennett, E. Yelverton, P. H. Seeburg, H. L. Heyneker, D. V. Goeddel, and D. Collen, Cloning and expression of human tissue-type plasminogen activator cDNA in E. coliNature, 301:214–221 (1983).
S. V. Pizzo, M. L. Schwartz, R. L. Hill, and P. A. McKee, The effect of plasmin on the subunit structure of fibrinogen, J. Biol. Chem., 247:636–645 (1972).
P. Rentrop, H. Blanke, K. R. Karsch, W. Rutsch, M. Schartl, W. Merx, R. Dorr, D. Mathey, and K. Kuch, Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction, Am. Heart J., 102:1188–1193 (1981).
L. L. Shen, R. P. McDonagh, J. McDonagh, and J. Hermans, Early events in the plasmin digestion of fibrinogen and fibrin: effects of plasmin on fibrin polymerization, J. Biol. Chem., 252:6184–6189 (1977).
The TIMI Study Group, The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings, New. Eng. J. Med., 312:932–936 (1985).
F. Van de Werf, S. R. Bergmann, K. A. Fox, H. de Geest, C. F. Hoyng, B. E. Sobel, D. Cohen, and B. E. Sobel, Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology, Circulation, 69:605–610 (1984).
F. Van de Werf, P. A. Ludbrook, S. R. Bergmann, A. J. Tiefenbrunn, K. A. Fox, H. de Geest, M. Verstraete, D. Collen, and B. E. Sobel, Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction, N. Engl. J. Med., 310:609–613 (1984).
M. Verstraete, R. Bernard, M. Bory, R. W. Brower, D. Collen, D. P. de Bono, R. Erbel, W. Huhmann, R. J. Lennane, J. Lubsen, D. Mathey, J. Meyer, H. R. Michels, W. Rutsch, M. Schartl, W. Schmidt, R. Uebis, and R. von Essen, Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction, Lancet, 1:842 (1985).
M. Verstraete, W. Bleifeld, R. W. Brower, B. Charbonnier, D. Collen, D. P. de Bono, A. J. Dunning, R. J. Lennane, J. Lubsen, D. G. Mathey, P. L. Michel, Ph. Raynaud, J. Schofer, A. Vahanian, J. Vanhaeke, G. A. van de Kley, F. Van de Werf, and R. von Essen, Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction, Lancet, 2:965 (1985).
M. Verstrate, Intravenous administration of thrombolytic agent is the only realistic approach in evolving myocardial infarction, Eur. Heart J., 6:586 (1985).
S. Yusef, R. Collins, R. Peto, C. Furberg, M. J. Stampfer, S. Z. Goldhaber, and C. H. Hennekens, Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials, Eur. Heart J., 6:556 (1985).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Owen, J., Grossman, B., Sobel, J., Kudryk, B. (1990). Fibrinogen Proteolysis and Coagulation System Activation during Thrombolytic Therapy. In: Liu, C.Y., Chien, S. (eds) Fibrinogen, Thrombosis, Coagulation, and Fibrinolysis. Advances in Experimental Medicine and Biology, vol 281. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3806-6_43
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3806-6_43
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6697-3
Online ISBN: 978-1-4615-3806-6
eBook Packages: Springer Book Archive